Clinical trials: Glioblastoma
Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive…
- Trial name
- NCT06061809
- Testing
- Bevacizumab, PD-L1 t-haNK, N-803
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- ImmunityBio, Inc.
Glioblastoma (GBM)
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt).
- Trial name
- NCT06805305
- Testing
- DOC1021, Tumor resection, Temodar (Temozolomide)
- Where
- 18 sites in United States
- Volunteers
- 180 people
- Sponsor
- Diakonos Oncology Corporation
Glioblastoma
Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma
Glioblastoma is a rare, aggressive brain tumor that leads to death within 2 years of diagnosis in more than half of patients. There are currently 123 studies ongoing that are testing treatments for glioblastoma.
- Trial name
- NCT07674095
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- BPGbio
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Glioblastoma Multiforme of Brain
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the…
- Trial name
- NCT05627323
- Testing
- CHM-1101 CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Chimeric Therapeutics
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Glioblastoma Multiforme
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- TEM-GBM (NCT03866109)
- Testing
- Temferon
- Where
- 3 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Genenta Science
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Recurrent Glioblastoma Multiforme(GBM)
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
- Trial name
- NCT05053880
- Testing
- ACT001, ACT001 + Pembrolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accendatech USA Inc.
Astrocytoma, Grade IV, Glioblastoma
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
A Phase 1/2a Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001 in Combination with Recombinant Human Interleukin-2 in Adults with Recurrent Resection Eligible IDH1 wild-type Glioblastoma.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Trial name
- CYNK001GBM02 (NCT05218408)
- Testing
- CYNK-001 systemic and Intra cavity administration
- Sponsor
- Celularity Incorporated
Glioblastoma, Refractory Glioblastoma
Expanded Access to Gallium Maltolate (GaM)
The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments.
- Conditions
- Glioblastoma, Refractory Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT06404034
- Testing
- Gallium Maltolate
- Where
- 3 sites in United States
- Sponsor
- Imaging Biometrics, LLC
Glioblastoma, Brain Tumors
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma.
- Conditions
- Glioblastoma, Brain Tumors, Brain Imaging
- Trial name
- EARLYBRAINPET (NCT07274397)
- Testing
- Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Beta Emitting Accurate Monitored Systems
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Glioblastoma Multiforme
Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial
The clinical investigation is a non-randomized, multicenter, open-label, prospective, exposure-time escalation clinical investigation.
- Trial name
- OMX-EFS-01 (NCT06533163)
- Testing
- Oncomagnetic device
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- BioTex, Inc.
Glioblastoma
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
The trial is an open, multicenter, explorative, pilot phase II study in a small number of patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy (iPDT) with PD L 506 in newly diagnosed…
- Trial name
- NCT03897491
- Testing
- 5-aminolevulinic acid
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- photonamic GmbH & Co. KG
Primary Glioblastoma
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18…
- Trial name
- NCT05736406
- Testing
- 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
- Where
- 2 sites in United States, France
- Volunteers
- 12 people
- Sponsor
- Hemerion Therapeutics
Glioblastoma
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2…
- Trial name
- NOVA-GBM (NCT07604285)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG)
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
The objective of this clinical investigation is to assess the safety and performance of the SonoClear® System. Performance will be assessed by analysis of the contrast-to-noise ratio (CNR) and assessment of image quality by using…
- Conditions
- Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG), Glioblastoma
- Trial name
- NCT07042620
- Testing
- SonoClear(R) System
- Where
- 4 sites in Germany
- Volunteers
- 15 people
- Sponsor
- SonoClear AS
Glioblastoma Multiforme
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
- Trial name
- NCT03382977
- Testing
- VBI-1901, Carmustine, Lomustine
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- VBI Vaccines Inc.